T.J Brier - School of Life and Environmental Sciences, University of Nottingham

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 38 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

A Phase 1 Dose Escalation and Expansion Trial of the Next-Generation Oral SERD Camizestrant in Women with ER-positive, HER2-negative Advanced Breast Cancer: SERENA-1 Monotherapy Results

E. Hamilton, M. Oliveira,N. Turner,J. Garcia-Corbacho, C. Hernando,E. M. Ciruelos, P. Kabos,M. Ruiz-Borrego, A. Armstrong,M. R. Patel,C. Vaklavas, C. Twelves, V. Boni, J. Incorvati,T. Brier, L. Gibbons,T. Klinowska,J. P. O. Lindemann,C. J. Morrow,A. Sykes, R. D. Baird

Annals of oncology official journal of the European Society for Medical Oncologyno. 8 (2024): 707-717

Cited3Views0WOSBibtex

754P Initial Results from a First-in-human Study of AZD5335, a Folate Receptor Α (Frα)-Targeted Antibody-Drug Conjugate, in Patients (pts) with Platinum-Resistant Recurrent Ovarian Cancer (PRROC)

R. Shapira-Frommer,K. Sudo,K. Harano,L. Mileshkin,R. Perets, M. Song, J. Cohen, Y-F. Huang,H. Ambrose,T. Brier, A. Dosani,P.G. Fraenkel, A. Kmieciak,P. Mitchell, C. Myers, J. Wang, R.I. Odegbami,A. Sykes, S. Turner,F. Meric-Bernstam

Annals of Oncology (2024): S572-S573

Cited0Views0Bibtex

Abstract P3-07-28: SERENA-1: Updated Analyses from a Phase 1 Study of the Next Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Combined with Abemaciclib, in Women with ER-positive, HER2-negative Advanced Breast Cancer

Cancer Research（2023）

Cited1Views0Bibtex

819Tip FONTANA: A Phase I/IIa Study of AZD5335 As Monotherapy and in Combination with Anti-Cancer Agents in Patients with Solid Tumours

F. Meric-Bernstam, M. Song,S.N. Westin,G. Au-Yeung,P. Mitchell, C. Myers, M. Gymnopoulos,P.G. Fraenkel, M. Nawinne,T. Brier,L. Mileshkin

Annals of Oncology (2023): S541

Cited0Views0Bibtex

SERENA-1: Updated Analyses from a Phase 1 Study of the Next Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Combined with Abemaciclib, in Women with ER-positive, HER2-negative Advanced Breast Cancer

CANCER RESEARCHno. 5 (2023)

Cited0Views0Bibtex

FONTANA: A Phase I/IIa Study of AZD5335 As Monotherapy and in Combination with Anti-Cancer Agents in Patients with Solid Tumours

F. Meric-Bernstam, M. Song,S. N. Westin,G. Au-Yeung,P. Mitchell, C. Myers, M. Gymnopoulos,P. G. Fraenkel, M. Nawinne,T. Brier,L. Mileshkin

ANNALS OF ONCOLOGY (2023): S541-S541

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn